乳腺癌SPECT分子显像靶点基础研究进展

doi:10.11904/j.issn.1002-3070.2016.03.016

摘要/Abstract

摘要： 近年来乳腺癌的分子显像水平逐渐进步,更多特异性的显像靶点被发现。本文对比了几组基础实验较为成熟的乳腺癌SPECT分子显像靶点:小鼠双微体扩增基因(Murine double minute2,MDM2)、磷酸化组蛋白(Phosphorylated H2AX,γH2AX)、膜联蛋白V(Annexin V)、表皮生长因子受体(Epidermal growth factor receptor,EGFR)、人表皮生长因子受体2(Human epidermal growth factor receptor-2,HER-2)等。并综述了这些靶点及显像技术的研究现状,为乳腺癌SPECT分子显像的发展奠定基础。

关键词: 乳腺癌, SPECT, 双微体扩增基因, 磷酸化组蛋白, 膜联蛋白V

Abstract: The technique of molecular imaging of breast cancer has made great advances in recent years,more and more specific targets were found.This article compares several successful breast cancer targets of molecular imaging with SPECT,such as MDM2,γH2AX,Annexin V and HER-2 etc.This paper reviews the research status of these targets and imaging techniques to lay the foundation for further progress of molecular imaging for breast cancer with SPECT.

Key words: Breast cancer, SPECT, MDM2, γH2AX, Annexin V

中图分类号:

R737.9

王欣宇, 阚清鹏综述, 赵长久审校. 乳腺癌SPECT分子显像靶点基础研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 271-274.

WANG Xinyu,KAN Qingpeng,ZHAO Changjiu. Advanced basic research on breast cancer targets of molecular imaging with SPECT[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 271-274.

参考文献

1 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
2 李亚明.进入多模态、分子显像新时代的核医学[J].山西医科大学学报,2014,45(3):165-166.
3 中华医学会核医学分会.乳腺核医学检查共识[J].中华放射学杂志,2014,48(9):726-729.
4 Fu P,Shen B,Zhao C,et al.Molecular imaging of MDM2 messenger RNA with ^99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts[J].J Nucl Med,2010,51(11):1805-1812.
5 Cornelissen B,Kersemans V,Darbar S,et al.Imaging DNA damage in vivo using H2AX-targeted immunoconjugates[J].Cancer Research,2011,71(13):4539-4549.
6 罗瑞,王峰,侯彦杰,等.99Tcm-TP5-3 microSPECT/CT探测乳腺癌化疗后细胞凋亡的实验研究[J].中华核医学与分子影像杂志,2014,34(4):312-316.
7 Vallis KA,Reilly RM,Scollard D,et al.Phase I trial to evaluate the tumor and normal tissue uptake,radiation dosimetry and safety of(111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer[J].Am J Nucl Med Mol Imaging,2014,4(2):181-192.
8 Ahlgren S,Orlova A,Wallberg H,et al.Targeting of HER2-expressing tumors using ¹¹¹In-ABY-025,a second-generation affibody molecule with a fundamentally reengineered scaffold[J].J Nucl Med,2010,51(7):1131-1138.
9 Li H,Liu Q,Wang Z,et al.The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast Cancer[J].J Bio Chem,2015,290(37):22649-22661.
10 Senturk E,Manfredi JJ.Mdm2 and tumorigenesis:evolving theories and unsolved mysteries[J].Genes Cancer,2012,3(3-4):192-198.
11 Chen X,Qiu J,Yang D,et al.MDM2 promotes invasion and metastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9[J].PLoS One,2013,8(11):e78794.
12 Qin JJ,Nag S,Voruganti S,et al.Natural product MDM2 inhibitors:anticancer activity and mechanisms of action[J].Curr Med Chem,2012,19(33):5705-5725.
13 Sepideh S,Mohammadreza JN,Ali D,et al.Study of the Murine Double Minute 2 status in patients with gastric and colorectal carcinomas and its correlation with prognostic factors[J].Indian J Pathol Microbiol,2012,55(2):192-195.
14 Rayburn ER,Ezell SJ,Zhang R.Recent advances in validating MDM2 as a cancer target[J].Anticancer Agents Med Chem,2009,9(8):882-903.
15 Park HS,Park JM,Park S,et al.Subcellular localization of Mdm2 expression and prognosis of breast cancer[J].Int J Clin Oncol,2014,19(5):842-851.
16 Fu P,Sun L,Cao X.MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in human breast cancer xenograft[J].Mol Imaging,2014,13(2):1-10.
17 曾群力.γH2AX[J].中华预防医学杂志,2006,3(40):158.
18 Ciccia A,Elledge SJ.The DNA damage response:making it safe to play with knives[J].Molecular Cell,2010,40(2):179-204.
19 Bartek J,Lukas J,Bartkova J.DNA damage response as an anti-cancer barrier:damage threshold and the concept of ′conditional haploinsufficiency′[J].Cell Cycle,2007,6(19):2344-2347.
20 崔铭,刘杨,王光熙,等.DNA损伤标志物γH2AX及其在临床肿瘤研究中的应用[J].中华病理学杂志,2014,43(10):714-717.
21 Bhatia A,Dey P,Goel S,et al.Expression of gammaH2AX may help in defining a genetically more stable subtype of infiltrating ductal carcinoma of breast[J].Indian J Med Res,2013,137(4):759-766.
22 Cornelissen B,Kersemans V,Darbar S,et al.Imaging DNA damage in vivo using gamma H2AX-targeted immunoconjugates[J].Cancer Research,2011,71(13):4539-4549.
23 Schaper FL,Reutelingsperger CP.^99mTc-HYNIC-Annexin A5 in oncology:evaluating efficacy of anti-cancer therapies[J].Cancers,2013,5(2):550-568.
24 Deng S,Wang J,Hou L,et al.Annexin A1,A2,A4 and A5 play important roles in breast cancer,pancreatic cancer and laryngeal carcinoma,alone and/or synergistically[J].Oncol Lett,2013,5(1):107-112.
25 Siena S,Sartore-Bianchi A,Di Nicolantonio F,et al.Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer[J].J Nati Cancer Inst,2009,101(19):1308-1324.
26 Silva AR.Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation[J].Int J Surg Pathol,2006,14(3):268-269.
27 邓再兴,俞文菊,朱凯.乳腺癌组织CK5/6与EGFR表达及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(19):1477-1480.
28 孙刚,杨乐,董朝,等.不同亚型乳腺癌组织中EGFR、PI3 K及其磷酸化表达差异和特征分析[J].中华内分泌外科杂志,2014,3(8):207-212.
29 王荣荣,刘晓,陆苏,等.乳腺癌中BAG-1 EGFR和PARP-1的表达及其临床意义[J].中国肿瘤临床,2014,41(13):866-871.
30 Reilly RM,Chen P,Wang J,et al.Preclinical pharmacokinetic,biodistribution,toxicology,and dosimetry studies of ¹¹¹In-DTPA-human epidermal growth factor:an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer[J].J Nucl Med,2006,47(6):1023-1031.
31 赵新明,韩静雅,贾立镯.脂质体介导TCm-EG荷SKOV3卵巢癌裸FR mRNA反义肽核酸在鼠体内的分布及显像[J].中华核医学与分子影像杂志,2014,5(34):379-384.
32 李晓琳,谢鹏,孟雪,等.表皮生长因子受体分子显像与基因突变在非小细胞肺癌中的研究进展[J].中华核医学与分子影像杂志,2012,32(5):393-396.
33 刘秋雨,孔令非,刘正国.乳腺癌HER-2基因检测的临床价值[J].中华实用诊断与治疗杂志,2010,24(8):778-780.
34 李欣,蔡炯.HER-2放射性配体Tcm-ABH2的制备及荷乳腺癌裸鼠显像[J].中华核医学与分子影像杂志,2015,3(35):222-226.
35 Sorensen J,Sandberg D,Sandstrom M,et al.First-in-human molecular imaging of HER-2 expression in breast cancer metastases using the ¹¹¹In-ABY-025 affibody molecule[J].J Nucl Med,2014,55(5):730-735.
36 Razumienko E,Dryden L,Scollard D,et al.MicroSPECT/CT imaging of co-expressed HER-2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates[J].Breast Cancer Res Treat,2013,138(3):709-718.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[12]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[13]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[14]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[15]	李红阳, 孙亮, 姜醒, 苑光军, 刘艳. 蝙蝠葛碱在人乳腺癌MCF-7细胞对5氟尿嘧啶敏感性的研究[J]. 实用肿瘤学杂志, 2017, 31(5): 385-389.